Compare NBR & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBR | SPTX |
|---|---|---|
| Founded | 1952 | N/A |
| Country | Bermuda | United States |
| Employees | 13900 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2026 |
| Metric | NBR | SPTX |
|---|---|---|
| Price | $81.63 | $21.25 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $75.00 | N/A |
| AVG Volume (30 Days) | ★ 282.1K | 206.6K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.65 | N/A |
| Revenue Next Year | $4.88 | N/A |
| P/E Ratio | $4.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.50 | $17.59 |
| 52 Week High | $112.90 | $22.98 |
| Indicator | NBR | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 62.35 |
| Support Level | $75.43 | $17.89 |
| Resistance Level | $83.77 | $21.59 |
| Average True Range (ATR) | 3.47 | 1.88 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 50.57 | 68.80 |
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.